Pulmonary Arterial Hypertension: Upfront Triple Therapy and the Shift Away from Sequential Escalation
DOI:
https://doi.org/10.5281/zenodo.22365930Abstract
For most of its modern treatment era, pulmonary arterial hypertension was managed the way much of chronic
cardiovascular disease still is: start one drug, and add a second or third only once the first has visibly failed. That
sequential-escalation default has been challenged directly by randomized trials testing upfront combination therapy from the
moment of diagnosis, first as two drugs together, and more recently as three
References
Galie N, Barbera JA, Frost AE, et al. "Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension" (AMBITION). N Engl J Med 373(2015):834-844.
Chin KM, Sitbon O, Doelberg M, et al. "Three- versus Two-Drug Therapy for Patients with Newly Diagnosed Pulmonary Arterial Hypertension" (TRITON). J Am Coll Cardiol 78(2021):1393-1403.
Humbert M, Kovacs G, Hoeper MM, et al. "2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension". Eur Heart J 43(2022):3618-3731.
